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BACKGROUND: Trastuzumab resistance hampers its well-known efficacy to control HER2-positive breast cancer. The involvement of
PI3K/Akt pathway in this mechanism is still not definitively confirmed.
METHODS: We selected 155 patients treated with trastuzumab after development of metastasis or as adjuvant/neoadjuvant therapy.
We performed immunohistochemistry for HER2, ER/PR, epidermal growth factor 1-receptor (EGFR), a-insulin-like growth factor
1-receptor (IGF1R), phosphatase and tensin homologue (PTEN), p110a, pAkt, pBad, pmTOR, pMAPK, MUC1, Ki67, p53 and p27;
mutational analysis of PIK3CA and PTEN, and PTEN promoter hypermethylation.
RESULTS: We found 46% ER/PR-positive tumours, overexpression of EGFR (15%), a-IGF1R (25%), p110a (19%), pAkt (28%), pBad
(22%), pmTOR (23%), pMAPK (24%), MUC1 (80%), PTEN loss (20%), and PTEN promoter hypermethylation (20%). PIK3CA and
PTEN mutations were detected in 17% and 26% tumours, respectively. Patients receiving adjuvant trastuzumab with a-IGF1R or pBad
overexpressing tumours presented shorter progression-free survival (PFS) (all Pp0.043). Also, p110a and mTOR overexpression, liver
and brain relapses implied poor overall survival (OS) (all Pp0.041). In patients with metastatic disease, decreased PFS correlated with
p110a expression (P¼ 0.024), whereas for OS were the presence of vascular invasion and EGFR expression (Pp0.019; Cox analysis).
CONCLUSION: Our results support that trastuzumab resistance mechanisms are related with deregulation of PTEN/PI3K/Akt/mTOR
pathway, and/or EGFR and IGF1R overexpression in a subset of HER2-positive breast carcinomas.
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Breast cancer (BC) is one of the most frequent malignancies in
women (Jemal et al, 2008). HER2 overexpressing and/or gene
amplified tumours represent approximately 25% of all BC, and
they are associated with an aggressive phenotype, metastases,
resistance to chemotherapy (CT), and poor prognosis (Slamon
et al, 1987, 1989; Peiro et al, 2007; Nguyen et al, 2008). Never-
theless, the outcome has changed dramatically with the introduc-
tion of trastuzumab, a humanised monoclonal antibody that
targets the HER2 extracellular domain (Murphy and Modi, 2009).
It is very effective in combination with CT for the treatment of
early stages (Viani et al, 2007) or metastatic BC (Pegram et al,
2004; Brufsky et al, 2005), and even as a single-agent for the later
group (Vogel et al, 2002), showing in both groups of patients a
substantial decrease in cancer recurrence and mortality (Slamon
et al, 2001; Piccart-Gebhart et al, 2005; Joensuu et al, 2006; Untch
et al, 2008). Despite its demonstrated clinical benefit, about
30–50% of patients do not respond, and those with metastasis that
achieved an initial response to trastuzumab-based regimens will
develop drug resistance.
Currently, in clinical practice there are not conclusive biomar-
kers that allow the selection of patients who will respond to
trastuzumab and the exact molecular mechanisms are still not well
defined. Several growth factor receptors and signalling molecules
have been proposed to be responsible for trastuzumab resistance,
such as downregulation of the surface HER2 protein by endocytosis
and degradation (Austin et al, 2004), p27 downregulation (Lane
et al, 2001; Nahta et al, 2004), activation of insulin-like growth
factor 1-receptor (IGF1R) (Lu et al, 2001; Nahta et al, 2005),
interaction between HER2 and epidermal growth factor 1-receptor
(EGFR) (Diermeier et al, 2005), phosphatase and tensin homologue
(PTEN) loss (Nagata et al, 2004), phosphoinositide 3-kinase (PI3K)/
Akt activation (Esteva et al, 2011; Razis et al, 2011), MUC1 (Fessler
et al, 2009) and MUC4 upregulation (Nagy et al, 2005), and the
crosstalk with the ER signalling pathway (Slamon et al, 2001). More
recently, the non-receptor tyrosine kinase c-SRC (SRC) has been
suggested as a potential key modulator of trastuzumab response
(Zhang et al, 2011).
Therefore, the aim of our study was to evaluate the relevance of
alterations in the PI3K/Akt/mTOR and Ras/mitogen-activated
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protein kinase (MAPK) signalling pathways, given their role in cell
cycle progression. We performed an extensive immunohistochem-
ical and molecular analysis of several biological markers related
with these pathways, in a series of patients with HER2-positive BC
in stage I-IV, to determine their prognostic relevance, and as a
result, their potential involvement in the mechanisms of response
to trastuzumab.
PATIENTS AND METHODS
Tumour samples and patients’ follow-up
The study was conducted according to the Declaration of Helsinki
principles, with approval from the local ethics committees. A total of
155 tumour samples from HER2-positive patients were retro-
spectively collected from the Department of Pathology of the
Hospital de la Santa Creu i Sant Pau (n¼ 103) and University
General Hospital of Alicante (n¼ 52). Patients were staged according
to the WHO system, and tumours were histologically graded
according to Elston and Ellis method. After pathological diagnosis,
patients were treated according to standard protocols. All patients
received trastuzumab for the treatment of metastatic disease (n¼ 75)
after failure of conventional CT with anthracyclines and/or taxanes,
or for early stages either adjuvant (n¼ 40) or neoadjuvant (n¼ 27)
therapy. In 13 patients the type of treatment was unknown. Median
follow-up was 5.3 years (range 0.17–31 years).
We considered response or non-resistance to trastuzumab
treatment when no progression of stable disease occurred.
Progression-free survival was defined as the length of time after
treatment during which a patient survived with no signs of the
disease, and OS as the time to the patients’ death or last follow-up.
Immunohistochemistry
Tissue microarrays were prepared from paraffin-embedded tissue
taken from three representative tumour areas. Sections were
stained using the Envision method (Dako, Glostrup, Denmark).
HER2 protein and EGFR protein determinations were performed
using HercepTest and EGFR pharmaDx (Dako; Glostrup, Denmark),
respectively. Antibodies, dilutions, antigen retrieval methods, and
suppliers are listed in Table 1. ER/PR and HER2 were evaluated by
standard protocols. The EGFR expression was considered positive
when complete membrane staining is 410% of tumour cells. The
PTEN, pAkt, pBad, p110a, p-mTOR, a-IGF1R, MUC1, and pMAPK
(cytoplasm) scores were calculated by multiplying the percentage of
labelled cells by the staining intensity (range 0–300). Loss of PTEN
was considered for cutoff scoreso75; and overexpression of p110a,
MUC1, pMAPK, p27 and pAkt were considered for scores X150.
Positive a-IGF1R and mTOR were considered for scoresX220 and
X30, respectively. The percentage of stained nuclei was evaluated
independently of the intensity for Ki67 (cutoff 20%) and p53 (cutoff
10%). Consensus between three pathologists (AG, EL, and GP) was
done for the immunohistochemical results.
Mutational analysis of PIK3CA
Genomic DNA was extracted from frozen tumour or paraffin-
embedded tissues and mutational analysis of PIK3CA was
performed by PCR and direct sequencing using primers for exons
9 and 20 as previously described (Samuels et al, 2004).
Phosphatase and tensin homologue mutation and
promoter hypermethylation
Mutational analysis was performed using previously reported PCR
conditions and primers for exons 3, 5, 7, and 8 (Bussaglia et al,
2000). Methylation-specific PCR was used to assay CpG island
methylation status of the PTEN promoter gene using the
Methylamp One-Step DNA Modification kit (Epigentek, Brooklyn,
NY, USA). Three primers sets were used for the PCR as previously
reported (Soria et al, 2002).
In situ hybridisation analysis
HER2 gene status was confirmed by fluorescence in situ
hybridisation (Dako pharmaDx) or chromogenic in situ hybridisa-
tion (Spot light; Zymed, Paisley, UK) in equivocal cases.
Statistical analyses
They were performed with the SPSS/win 17. 0 statistical software
package (SPSS, Chicago, IL, USA). Qualitative variables were
compared with the X2/Fisher tests. A receiver operating char-
acteristic curve and area under the curve were generated to
determine a cutoff value of the expression of several biomarkers
and the potential clinical utility to predict prognosis. The Kaplan–
Meier method and the Cox regression model were used to estimate
survival. P-values o0.05 were considered statistically significant.
RESULTS
Clinicopathological data
The clinicopathological data is summarised in Table 2. Patients
were classified into two groups: group A (n¼ 75) included patients
where trastuzumab was included for treatment of metastatic
disease and group B (n¼ 67 patients) those with trastuzumab in
the adjuvant/neoadjuvant setting. Median age was 55 years (range
31–92 years) and median tumour size was 2.5 cm (range 1– 20 cm).
Histological grade 1 was seen in 7 (5%) cases, grade 2 in 50 (32%),
Table 1 Panel of antibodies for the immunohistochemical analysis
Antibody Clone Dilution Supplier Pretreatment
ER 6F11 1 : 40 Novocastra (Newcastle, UK) Citrate buffer pH 6. Autoclave, 8min
PR 16 1 : 200 Novocastra (Newcastle, UK) Citrate buffer pH 6. Autoclave, 8min
aIGF1R 24–31 1 : 200 Neomarkers (Freemont, CA, USA) Citrate buffer pH 6. Autoclave, 8min
PTEN 6H2.1 1 : 50 Cascade Biosciences (Winchester, MA, USA) Citrate buffer pH 6. Autoclave, 40min
p110a Rabbit polyclonal 1 : 25 Cell Signaling (Beverly, MA, USA) EDTA buffer pH 8. Autoclave, 8min
pAkt Rabbit monoclonal 1 : 50 Cell Signaling (Beverly, MA, USA) EDTA buffer pH 8. Autoclave, 8min
pBAD Sc-12969-R 1 : 40 Santa Cruz (Santa Cruz, CA, USA) EDTA buffer pH 8. Autoclave, 8min
mTOR Rabbit polyclonal 1 : 50 Cell Signaling (Beverly, MA, USA) EDTA buffer pH 8. Autoclave, 8min
MUC1 BC-2 1 : 40 Signet (Dedham, MA, USA) Citrate buffer pH 6. Autoclave, 8min
pMAPK Rabbit IgG monoclonal 1 : 100 Cell Signaling (Beverly, MA, USA) EDTA buffer pH 8. Autoclave, 8min
Ki67 MIB-1 Prediluted Dako (Carpinteria, CA, USA) Citrate buffer pH 6. Autoclave, 8min
p53 DO-7 Prediluted Dako (Carpinteria, CA, USA) Citrate buffer pH 6. Autoclave, 8min
p27 SX53G8 1 : 50 Dako (Carpinteria, CA, USA) EDTA buffer pH 8. Autoclave, 8min
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and grade 3 in 98 (63%) tumours. Vascular invasion was found in
32% (47 of 145) cases. Axillary lymph node dissection was
performed in 135 patients, being positive in 89 cases (66%).
Tumour stage was IA in 17 (11%) patients, IIA in 29 (18.8%), IIB in
15 (9.7%), IIIA in 42 (27%), IIIB in 18 (11.6%), IIIC in 12 (7.7%),
IV in 13 (8.4%), and was unknown in 9 (5.8%) patients. A total of
11 patients were lost in the follow-up, and among those remaining,
56 (39%) were alive with no evidence of disease, 31 (21.5%) alive
with disease, and 57 (39.5%) died of the disease (DOD).
Tumour molecular features
Table 3 includes the relationship between clinicopathological and
molecular data for all patients. Examples of relevant immunohis-
tochemical images are shown in Figure 1.
Hormonal receptors (HR) The HR (either ER or PR) were positive
in 46% (67/145) of the tumours, and they were associated with
ductal formation (P¼ 0.024) and histological grade 1 (P¼ 0.048).
Growth factor receptors Increased EGFR expression was found in
15% tumours (21/141) and correlated with high mitotic index
(P¼ 0.013) and negative HR (Po0.000), and there was a trend
towards higher tumour grade (P¼ 0.061).
Staining of a-IGF1R was strong and diffuse (overexpression) in
25% tumours (34/138), in association with high grade (P¼ 0.001),
high mitotic index (P¼ 0.004), and vascular invasion (P¼ 0.005).
Biomarkers associated with the PI3K/Akt/mTOR and MAPK
signalling pathways Phosphatase and tensin homologue loss
was found in 20% of the tumours (30/149), PTEN promoter
hypermethylation in 20% (22/110) and mutations in 26% (8/30).
Phosphatase and tensin homologue loss was associated with
vascular invasion (P¼ 0.047) and higher grades (P¼ 0.065), but
Table 2 Summary of the main clinicopathological data
All cases
(n¼ 155)
Trastuzumab in
the metastatic
disease (n¼ 75)
Trastuzumab in
the first-line
treatment
(n¼67)
Age
(median and range)
55 years
(31–92 years)
59 years
(31–92 years)
54 years
(33–88 years)
Tumour size
(median and range)
2.5 cm
(1–20 cm)
2.8 cm
(1–11 cm)
2.4 cm
(4–20 cm)
BC subgroups
HER2+/HR+ 67 35 29
HER2+/HR 78 33 37
Unknown 10 7 1
Lymph node status
Negative 46 20 24
Positive 89 47 36
Unknown 20 8 7
Stage
IA 17 8 8
IIA 29 10 17
IIB 15 8 6
IIIB 42 22 17
IIIA 18 13 5
IIIC 12 9 3
IV 13 3 7
Unknown 9 2 4
Histological grade
1 7 1 4
2 50 24 23
3 98 50 40
DCIS
o25% 25 12 12
425% 22 9 13
Follow-up
NED 56 5 50
AWD 31 21 10
DOD 57 49 7
LFU 11 0 0
Abbreviations: AWD¼ alive with disease; BC¼ breast carcinoma; DCIS¼ ductal
carcinoma in situ; DOD¼ dead of the disease; HR¼ hormonal receptors; LFU¼ lost
of follow-up; NED¼ no evidence of disease.
Table 3 Statistical correlations between clinicopathological, immunohis-
tochemical and molecular data for all tumours
Histological
grade
Ductal
form
Nuclear
grade Mitosis
Lymph
node +
Vascular
invasion
HR 0.080a 0.024a NS 0.091a NS NS
EGFR+ 0.061 0.083 NS 0.013 0.088 NS
aIGF1R+ 0.001 NS 0.07 0.004 NS 0.005
PTEN loss 0.065 NS NS NS NS 0.047
PIK3CA mut NS NS 0.043 NS NS NS
pAkt+ NS NS NS NS NS NS
pBad+ 0.001 NS 0.008 0.002 NS 0.006
mTOR+ NS NS 0.034 NS 0.12 NS
MAPK+ 0.029a NS NS NS NS NS
Ki67 420% 0.087 NS NS 0.021 NS 0.082
p53 410% NS NS 0.009 0.076 NS NS
p27+(nuclear) NS NS NS NS NS NS
Abbreviations: EGFR¼ epidermal growth factor 1-receptor; HR¼ hormonal recep-
tors; IGF1R¼ insulin-like growth factor 1-receptor; MAPK¼mitogen-activated
protein kinase; NS¼ non-significant; PTEN¼ phosphatase and tensin homologue.
aInverse relationship.
EGFR
p110a pAKT
PTEN pBAD
IGFR
Figure 1 Immunohistochemical expression of EGFR, aIGFR, p110a,
pAKT, pBad, and loss of PTEN in HER2-positive breast carcinomas.
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neither association with PTEN mutation nor hypermethylation was
found.
p110a (PI3K catalytic subunit) overexpression was present in 19%
of the tumours (24/125), and PIK3CA somatic missense mutations
were identified in 17% (24/142): in exon 20 (nucleotide A3140G,
amino acid H1047R) in 15% of the tumours (21/142), whereas
mutations in the helical domain of exon 9 (nucleotide G1635C,
amino acid E545D) were detected in only 6% (3/50). Interestingly,
mutations were present more frequently in tumours with EGFR
expression (33%; P¼ 0.016) and higher nuclear grade (P¼ 0.043),
but there was no correlation with p110a protein expression.
pAkt overexpression was found in 28% of the tumours (40/143)
and phosphorylated (inactive) Bad in 22% (30/139) in association
with high nuclear (P¼ 0.008) and histological grades (P¼ 0.001),
elevated mitotic index (P¼ 0.002), and vascular invasion
(P¼ 0.006). mTOR overexpression was detected in 23% (33/142)
of the tumours, predominantly with high nuclear grade tumours
(P¼ 0.034), and in association with a-IGF1R (47%; Po0.000),
p110a (64%; P¼ 0.028) and pBad (65%; P¼ 0.027).
Strong pMAPK expression in 24% (22/93) of the tumours
predominated in those of low grade (P¼ 0.029); MUC1 was
overexpressed in 80% of the analysed tumours (77/96) but without
significant association with clinicopathological features.
Cell proliferation and apoptosis markers Ki67420% was seen in
51% of the tumours (73/144), related with high mitotic index
(P¼ 0.021). p53 overexpression was found in 30% of the tumours
(42/139) associated with HR-negative status (P¼ 0.022) and high
nuclear grade (P¼ 0.009). Only 17% (16/94) of the cases showed
p27 nuclear expression but unrelated with any clinical-pathological
factors.
Relationship between biomarkers and recurrence
In all, 61% of the patients developed distant metastases, which
were located in the liver (35%), bone (35%), lung (27%), lymph
nodes (21%), pleura (18%), central nervous system (CNS; 16%),
and skin (14%). Patients with HR-positive tumours presented
more frequently bone metastases (P¼ 0.008) compared with those
with HR-negative status. In contrast, tumours with a-IGF1R
overexpression rarely metastasised to the liver (P¼ 0.009), lung
(P¼ 0.002), bone (P¼ 0.031) or lymph nodes (P¼ 0.007). Patients
with p110a-positive tumours developed more frequently CNS
metastases (P¼ 0.029). The remaining proteins studied here
showed a trend or were not associated with any specific site of
dissemination (see Table 4).
Survival analyses
In order to perform the survival analysis in similar patients
groups, we excluded those that received neoadjuvant CT or stage
IV. Therefore, 51 patients remained in group A and 38 patients in
group B. Supplementary Figures 1 and 2 include the Kaplan–Meier
curves for both groups. Table 5 shows the results of the
multivariate analysis.
Metastatic BC (group A) A total of 47 patients (92%, 47/51) had
tumour recurrence with a median PFS of 2.6 years (range 1.01 to
11.64 years) and 65% (33/51) of the patients DOD with a median
OS of 7.5 years (range 0.17 to 21 years).
Univariate analysis (Kaplan– Meier; log rank test) showed that
shorter PFS was associated with vascular invasion (P¼ 0.042),
mutated PTEN (P¼ 0.045), EGFR (P¼ 0.026), p110a (P¼ 0.004),
pAkt overexpression (P¼ 0.016), and CNS metastases (P¼ 0.002).
Poor OS correlated with positive lymph node status (P¼ 0.013),
EGFR (P¼ 0.006), p110a (P¼ 0.079), pAkt overexpression
(P¼ 0.042), tumour stage (P¼ 0.003), and tumour relapses in the
liver (P¼ 0.059) or in CNS (P¼ 0.005).
Multivariate analyses for PFS revealed that only the presence of
metastases to the CNS (P¼ 0.020, HR 3.59, CI 1.23–10.51) and
p110a overexpression (P¼ 0.024, HR 2.75, CI 1.14–6.49) emerged
Table 4 Statistical significance according to metastatic site for all patients. (Note: EGFR, p53, p27, and MAPK expression levels were unrelated with
metastases)
Liver Bone CNS Skin and soft tissue Lung Pleura Lymph nodes
HR+ NS 0.008 NS 0.069a NS NS NS
ER+ NS 0.004 NS 0.082 NS NS NS
PR+ NS 0.044 NS 0.090 NS NS NS
aIGF1R+ 0.009a 0.031a NS NS 0.002a N.S. 0.007a
PTEN
 Loss expr NS NS 0.058 NS NS NS NS
 Mutat NS NS NS 0.065 NS 0.099 NS
p110a NS NS 0.0029 NS NS NS NS
PIK3CA
 Mutat NS NS NS NS 0.087 NS NS
pAkt+ NS 0.085 NS NS NS NS NS
mTOR+ 0.069 NS NS NS NS NS NS
Ki67 420% 0.011 0.011 0.037 NS NS 0.049 0.096
pBad+ 0.068 NS NS NS NS NS NS
Abbreviations: CNS¼ central nervous system; ER¼ oestrogen receptor; HR¼ hormonal receptors; IHC¼ immunohistochemistry; mutat¼mutations; NS¼ non-significant;
PR¼ progesterone receptor. aInverse relationship.
Table 5 Multivariate analysis of histological and biological factors for
patients with trastuzumab treatment in the metastatic disease (group A)
(Cox model)
Variables ß Hazard ratio 95% CI P-value
Disease-free survival
CNS metastasis 1.128 3.59 1.23–10.51 0.020
p110a 1.269 2.75 1.14–6.49 0.024
Overall survival
Vascular invasion 1.17 3.36 1.22–8.94 0.015
CNS metastasis 1.406 4.22 1.44–12.38 0.009
EGFR 1.630 5.25 1.32–20.92 0.019
Abbreviations: CNS¼ central nervous system; EGFR¼ epidermal growth factor
1-receptor.
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as significant predictors of relapse. Worse OS was seen for vascular
invasion (P¼ 0.015, HR 3.36; CI 1.22– 8.94), EGFR expression
(P¼ 0.019, HR 5.25; CI 1.32– 20.92), and metastases to the CNS
(P¼ 0.009, HR 4.22; CI 1.44– 12.38) (Cox regression model).
Early-stage BC (group B) Only 11% (4/38) of the patients had
tumour recurrence and 5% died from the tumour. These events
might be, however, related to the short follow-up of the majority of
the patients (median 2.82 years). Median PFS was 2.81 years (range
1.00–8.28 years) and for OS was 2.82 years (range 1.00–8.42 years).
Shorter PFS was associated with a-IGF1R (P¼ 0.028), pBad
overexpression (P¼ 0.003), and tumour recurrence in the liver
(P¼ 0.003) or the bone (P¼ 0.001). Poor OS correlated with high
tumour grade (Po0.000), overexpression of p110a (P¼ 0.041) and
mTOR (77 vs 100% in negative cases; P¼ 0.006), and tumour
recurrence in the liver (P¼ 0.009) and CNS (P¼ 0.011) (Kaplan–
Meier; log rank test). Nevertheless, the multivariate analysis (Cox
regression) showed that these results did not reach any statistically
significance, probably due to the small number of events in this group.
DISCUSSION
In the current study, we performed an extensive immunohisto-
chemical and molecular analysis of biological markers related with
the PI3K/Akt/mTOR and Ras/MAPK signalling pathways in a
series of HER2-positive BC patients who received trastuzumab for
metastatic disease or as first-line therapy in earlier stages. We
found that patients with primary tumours showing alterations in
EGFR and PTEN/PI3K/Akt had shorter PFS and OS despite
trastuzumab treatment when given at advanced stage (metastatic
disease), supporting their role in the mechanisms of response. Our
results in the group of patients in earlier stages who received
trastuzumab as adjuvant/neoadjuvant therapy demonstrated that
those having tumours with IGF1R overexpression and inactive Bad
had shorter PFS. Poorer OS was seen in patients who developed
metastatic disease especially in the brain and liver, and with p110a
and mTOR overexpressing tumours. Nevertheless, none of the
factors had an independent prognostic value, probably related with
the small number of events and short follow-up of this group.
PI3K/Akt signalling is one of the most critical cancer-promoting
pathways through upregulation of growth factor receptors (EGFR,
IGF1R, HER2, etc) or PTEN inactivation (Lu et al, 1999) and
recently considered a major determinant of trastuzumab resistance
(Nagata et al, 2004; Berns et al, 2007; Esteva et al, 2011; Razis et al,
2011). HER2 and EGFR coexpression has a considerable inhibitory
effect on this drug (Diermeier et al, 2005) and are associated with
poor prognostic factors such as high grade, negative HR status,
and vascular invasion (Abd El-Rehim et al, 2004). In agreement
with these findings, we found coexpression in 15%, which in turn
was related with PIK3CA mutations. Insulin-like growth factor
1-receptor has an important role in growth and invasiveness of BC
(Peiro et al, 2009, 2011) and recently has also been involved in
trastuzumab resistance (Lu et al, 2001; Nahta et al, 2005; Harris
et al, 2007). In fact, we found IGF1R overexpression in 25% of the
tumours, especially in those of early stage patients who developed
recurrences. Of note, there is considerable evidence that both
IGF1R and EGFR crosstalk in BC cells and their coactivation
occurs in approximately 25% of BC, related with poor outcome
(Harris et al, 2001, 2007; Lu et al, 2001; Abd El-Rehim et al, 2004).
Therefore, it would be expected that those patients would be more
likely to be resistant to trastuzumab.
PTEN encodes a protein that inhibits activation of the PI3K/Akt/
mTOR signalling pathway (Panigrahi et al, 2004). The PTEN
inactivation may be related with gene mutations (o5% of sporadic
BC) (Vanhaesebroeck and Alessi, 2000) or promoter hypermethy-
lation (20%) (Saal et al, 2005), resulting in PTEN loss that occurs
in about half of the tumours (Nagata et al, 2004; Lerma et al, 2008;
Esteva et al, 2011; Razis et al, 2011). Prior experimental studies
with SKBR3 and BT474 BC cells and in breast tumour xenografts
demonstrated that PTEN reduction confers resistance to trastuzu-
mab’s antitumour function, and this data was subsequently
confirmed in a group of patients (Nagata et al, 2004). In the
current study, PTEN loss or promoter hypermethylation were
observed both in 20% of the tumours but without association with
patient’s survival, despite their correlation with other adverse
clinicopathological data, such as vascular invasion and lymph
node metastases. Nevertheless, tumours with PTEN mutations
(26%) recurred more frequently in patients with metastatic
disease, supporting its contribution to trastuzumab resistance.
The PI3K/Akt pathway activation blocks apoptosis and promotes
cellular proliferation through interaction with different down-
stream effectors (Stemke-Hale et al, 2008; Di Cosimo and Baselga,
2008; Nahta and O’Regan, 2011; Margariti et al, 2011). PIK3CA
activating mutations, clustered in exons 9 (helical domain) and 20
(kinase domain) have been reported in 18–40% BC, occasionally
associated with HER2 phenotype (Stemke-Hale et al, 2008) and
tumour recurrence (Razis et al, 2011). We found PIK3CA mutations
in 17% of the tumours, unrelated with trastuzumab clinical benefit.
In contrast, p110a overexpression (19%) had an independent poor
prognostic value for progression in patients with advanced stage.
Moreover, active Akt in 28% of our tumours, correlated with
recurrence and poor patients’ survival, supporting that activation of
this pathway contributes to tumour growth and therefore to
trastuzumab resistance. Further, inactive Bad seen in 22% of the
tumours in association with adverse prognostic parameters, such as
high tumour grade, high mitotic index and vascular invasion,
predicted shorter survival as a result of non-response, in early stage
patients. In partial agreement with our data, Esteva et al (2011),
in a previous series of 137 metastatic BC, found that PI3K path-
way activation (defined as PTEN loss and/or PIK3CA mutation)
significantly contributed to worse response to trastuzumab and
shorter OS. Moreover, pAkt and PTEN status combination showed
more power than PTEN loss alone.
mTOR is a key regulator of multiple cell stimuli integrating
growth factor and cytokine signals. In vitro studies and recent
clinical data have confirmed a relationship between mTOR and
HER2 (Morrow et al, 2011) as well as its role in trastuzumab
resistance (Nahta and O’Regan, 2011). In our series, 23% of
predominantly pleomorphic tumours contained increased mTOR,
and these patients had lymph-node metastasis. Of note, we found
that mTOR modulation by PI3K/Akt-dependent mechanisms
reflected by its positive correlation with p110a and Bad is
influenced by IGF1R. Further, supporting its involvement in the
mechanisms of trastuzumab responsiveness, all our patients from
the group B and negative mTOR tumours were alive at the last
follow-up compared with only 77% for those with positive
tumours. This is of interest as preclinical models have shown that
dual inhibition of both IGF1R – with either monoclonal antibodies
or tyrosine kinase inhibitors – and mTOR results in a superior
antiproliferative effect over each single strategy, and this
combination is now under evaluation in phase I/II trials in
patients with BC (Di Cosimo and Baselga, 2008). Nevertheless, the
mechanisms of how mTOR inhibitors reverse resistance to
trastuzumab still remain unexplained (Nahta and O’Regan, 2011).
The antiproliferative effect of trastuzumab has been also linked
to p27, cyclin E-CDK complex or IGF1R interaction in clinical and
in vitro studies (Lane et al, 2001; Lu et al, 2004; Nahta et al, 2004).
Nevertheless, we were not able to demonstrate any significant
correlation between p27, biomarkers or clinicopathological data.
MAPK/ERK pathway stimulation has been related with the
oncogenic potential of HER2 and trastuzumab resistance (Berns
et al, 2007; Yao et al, 2009). Nevertheless, recent data support the
assertion that trastuzumab has less effect on this cell cycle kinetics
pathway (Dave et al, 2011), and therefore, not relevant in the
development of resistance, in line with our study.
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Using a full-length MUC1 antibody, we found expression in 80%
of the tumours, with neither correlation with prognostic indicators
nor survival. Recent studies have now shown it is not related to
tumour growth but it is present in newly differentiated stem cells.
However, the cleaved form of the MUC1 protein (MUC1*) has
growth factor receptor-like activity on tumour cells and is detected
in populations of pluripotent stem cells (Hikita et al, 2008; Mahanta
et al, 2008). Fessler et al (2009) showed upregulation of MUC1* in
HER2-amplified/trastuzumab-resistant BC cells. Further treatment
with MUC1* antagonists in addition to trastuzumab reversed that
resistance (Fessler et al, 2009). Therefore, further studies on
MUC1* are needed to confirm the previous data in clinical series.
Finally, p53 and Ki67, two well-known prognostic factors (Jansen
et al, 1998; Yamashita et al, 2004) that were increased in a
significant number of tumours and associated with poor patholo-
gical features, lacked significance with respect to survival.
The results reported here mostly agree with those reported in
the literature derived from experimental and clinical series.
Nevertheless, our study was not conducted in patients included
in a clinical trial, and a control (no-trastuzumab) group was not
included. Therefore, the additional influence of CT and poor
prognostic factors to the markers associated with trastuzumab
resistance cannot be stated with certainty.
In summary, we found in about one-forth of HER2 tumours at
least one molecular alteration in the PI3K pathway and/or its
upstream or downstream effectors. Our data support the complex
interactions between EGFR, IGF1R, and the PTEN/PI3K/Akt/Bad
and mTOR signalling pathway, which in turn are potentially
related with the mechanisms of trastuzumab response. Never-
theless, some of these biomarkers need to be further validated in
larger series and introduced into the clinical practice to carefully
select patients on the basis of tumour molecular alterations. This is
of relevance as novel combinations for targeting simultaneously
several factors might suggest another strategy to overcome
trastuzumab resistance and enhance response rates.
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